Cancer clinical trials in the region Occitanie
300 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2 / Phase 3
Pancreas cancer
#NCT07076121
#2025-522598-12-00
Adenocarcinoma
Metastatic
MTAP
None
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Bristol-Myers Squibb
Phase 2 / Phase 3
Colon cancer
Rectal cancer
#NCT05462613
#2024-516709-22-00
Metastatic
1
Surgery
Chemotherapy
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier)
CHU de Besançon
Phase 2 / Phase 3
Pancreas cancer
#NCT05254171
#2024-514714-12-00
Adenocarcinoma
Metastatic
None
Systemic Treatment-Naive
BRCA 1/2
Centre Hospitalier Universitaire de Toulouse (Toulouse)
Panbela Therapeutics Inc
Phase 2
Stomach and esophageal cancer
#NCT06172478
#2023-507641-29-00
Carcinome épidermoïde de l’œsophage
Esophagus
Squamous cell carcinoma
Locally Advanced
Metastatic
2
Chemotherapy
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT06172478
#2023-507641-29-00
Carcinome urothélial
Invasive bladder cancer
Non-invasive bladder cancer
Upper excretory tract cancer
Urethral cancer
Locally Advanced
Metastatic
1
2
3 or more
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Breast cancer
#NCT06172478
#2023-507641-29-00
Cancer du sein
HER2 Negative
HR Positive
Locally Advanced
Metastatic
1
Chemotherapy
Targeted therapy
Hormone therapy
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Pancreas cancer
#NCT06172478
#2023-507641-29-00
Adénocarcinome du pancréas
Adenocarcinoma
Locally Advanced
Metastatic
1
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Prostate cancer
#NCT06172478
#2023-507641-29-00
Cancer de la prostate résistant à la castration
Adenocarcinoma
Metastatic Castration-resistant
1
2
3 or more
Chemotherapy
Hormone therapy
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Lung cancer
#NCT06172478
#2023-507641-29-00
Cancer du poumon
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
1
2
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
HER2
KRAS G12C
MET
NTRK-1/2/3
RET
ROS-1
Systemic Treatment-Naive
IUCT Oncopôle (Toulouse)
Daiichi Sankyo
Phase 2
Breast cancer
#NCT04985266
Phase de surveillance de l’ADN tumoral circulant
HER2 Negative
HR Positive
Localized
None
Surgery
Chemotherapy
Hormone therapy
Targeted therapy
IUCT Oncopôle (Toulouse)
Fiducie de la Fondation Royal Marsden NHS